Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From DexCom, Inc.
The big pharma company and its new partner both expect demand to continue for pre-exposure prophylaxis antibody therapies, for COVID-19 and beyond.
While it is still early days for Caribou, early signs suggest it could have the first off-the-shelf program to rival established CAR-T therapies.
Chad Patterson, Dexcom’s executive vice president of global marketing and product management, talked to Medtech Insight about the premium continuous glucose monitor manufacturer’s plans for facing stiff competition over the coming years.
Results of the ADAPT study presented at the Advanced Technologies & Treatments for Diabetes conference in Barcelona support Medtronic’s hope that the 780g insulin pump will help to turn around its diabetes business or make it an attractive acquisition for another company.
- Monitoring Equipment & Devices
In Vitro Diagnostics
- Glucose Testing
- Other Names / Subsidiaries
- SweetSpot Diabetes Care
- TypeZero Technologies, LLC